GMTX
NASDAQGemini Therapeutics Inc.
Gemini Therapeutics Inc. (GMTX) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for GMTX in the last 30 days. The most recent was published Feb 16, 2024.
Latest news
25 items- INSIDERFranchi Jean M. was granted 36,666 shares (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERSEC Form 3 filed by new insider Franchi Jean M.3 - Disc Medicine, Inc. (0001816736) (Issuer)
- 13D/GSEC Form SC 13G/A filed by Gemini Therapeutics Inc. (Amendment)SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)
- 13D/GSEC Form SC 13G/A filed by Gemini Therapeutics Inc. (Amendment)SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)
- 13D/GSEC Form SC 13G/A filed by Gemini Therapeutics Inc. (Amendment)SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)
- SECGemini Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Disc Medicine, Inc. (0001816736) (Filer)
- 13D/GSEC Form SC 13G/A filed by Gemini Therapeutics Inc. (Amendment)SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)
- 13D/GSEC Form SC 13D/A filed by Gemini Therapeutics Inc. (Amendment)SC 13D/A - Disc Medicine, Inc. (0001816736) (Subject)
- INSIDERBitterman Kevin sold $6,934,125 worth of shares (102,500 units at $67.65) (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERAtlas Venture Fund X, L.P. sold $10,147,500 worth of shares (150,000 units at $67.65) (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- SECSEC Form 144 filed by Gemini Therapeutics Inc.144 - Disc Medicine, Inc. (0001816736) (Subject)
- SECSEC Form 144 filed by Gemini Therapeutics Inc.144 - Disc Medicine, Inc. (0001816736) (Subject)
- INSIDERBitterman Kevin sold $1,280,000 worth of shares (20,000 units at $64.00) (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERAtlas Venture Fund X, L.P. sold $3,200,000 worth of shares (50,000 units at $64.00) (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- SECSEC Form 144 filed by Gemini Therapeutics Inc.144 - Disc Medicine, Inc. (0001816736) (Subject)
- SECSEC Form 144 filed by Gemini Therapeutics Inc.144 - Disc Medicine, Inc. (0001816736) (Subject)
- INSIDERQuisel John D exercised 2,700 shares at a strike of $1.01 (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERBryce Joanne exercised 3,000 shares at a strike of $9.86, increasing direct ownership by 120% to 5,500 units (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDEROrbimed Advisors Llc exercised 1,724 shares at a strike of $38.00 and sold $102,130 worth of shares (1,724 units at $59.24) (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERAshiya Mona sold $102,130 worth of shares (1,724 units at $59.24) and exercised 1,724 shares at a strike of $38.00 (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- SECSEC Form 144/A filed by Gemini Therapeutics Inc. (Amendment)144/A - Disc Medicine, Inc. (0001816736) (Subject)
- SECSEC Form 144/A filed by Gemini Therapeutics Inc. (Amendment)144/A - Disc Medicine, Inc. (0001816736) (Subject)
- SECSEC Form 144/A filed by Gemini Therapeutics Inc. (Amendment)144/A - Disc Medicine, Inc. (0001816736) (Subject)
- INSIDERAshiya Mona sold $24,584,100 worth of shares (433,200 units at $56.75) (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDEROrbimed Advisors Llc sold $24,584,100 worth of shares (433,200 units at $56.75) (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
GMTX FAQ
7 questionsWhat does Gemini Therapeutics Inc. do?
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) and linked ocular disorders. Its lead candidate is GEM103, a recombinant form of the human complement factor H protein that is in a Phase 2a trials in dry AMD patients with a complement factor H protein risk variant. The company was founded in 2015 and is based in Cambridge, Massachusetts.What is the latest news on GMTX?
Quantisnow has not tracked any new filings, ratings or press releases for GMTX in the last 30 days. The most recent wire item was published on February 16, 2024.Where does GMTX stock trade?
Gemini Therapeutics Inc. (GMTX) is listed on NASDAQ.What sector and industry is GMTX in?
Gemini Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about GMTX?
Across the last 7 analyst actions on Gemini Therapeutics Inc., there were 0 upgrades and 3 downgrades. The most recent action was from HC Wainwright & Co.: Neutral with a $2.00 price target on 2022-03-11.What companies are similar to GMTX?
Notable peers in the same industry include AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.), ABBV (AbbVie Inc.). Compare GMTX side-by-side with any of them on Quantisnow.How can I track GMTX on Quantisnow?
Quantisnow aggregates Gemini Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GMTX to receive live email and push alerts on every new disclosure.